STREAM trial: It is time to check out facilitated angioplasty?

It is not clear so far whether pre-hospital fibrinolysis with early angiography could provide a clinical outcome similar to primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). This study included 1,892 patients who presented within three hours of symptom onset and who could not undergo primary angioplasty within the first hour. Patients were randomized to primary angioplasty or fibrinolytic therapy with tenecteplase, (half dose in patients ≥ 75 years old), plus enoxaparin and clopidogrel before transport to a hospital capable of performing primary angioplasty. Angioplasty was performed as an emergency in case fibrinolysis failure, otherwise angiography was performed six to twenty-four hours after randomization. The primary outcome was a composite of death, shock, congestive heart failure or re-infarction at thirty days.

The primary outcome occurred in 116 of 939 patients (12.4%) of the fibrinolysis group and in 135 of 943 patients (14.3%) of the primary angioplasty group, (relative risk in the fibrinolysis group, 0.86, confidence interval 95%, 0.68 to 1.09, P = 0.21). Emergency angiography was required in 36.3% of patients of the fibrinolysis group, while the remaining patients underwent angiography seventeen hours after randomization on average. Intracranial hemorrhages were more frequent in the primary fibrinolysis group than in the angioplasty group, (1.0% versus 0.2%, p = 0.04, after the protocol change, 0.5% versus 0.3%, P = 0.45).

Conclusion: In brief, the STREAM study showed that pre-hospital fibrinolytic with early coronary angiography as necessary, is effective in AMI patients who could not undergo primary angioplasty within one hour after the first physician contact. However, fibrinolysis was associated with a slightly increased risk of intracranial hemorrhage.

Read article

frans_vande_worf_acc2013_presentacion
Frans Van de Worf
2013-03-12

Original title: The STREAM Trial: Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction.

More articles by this author

Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in patients without heart failure reduces mortality and...

SELECT ACS: The Inclacumab seems to reduce myocardial injury post angioplasty

P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is a recombinant monoclonal antibody against P-selectin, a...

Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in patients without heart failure reduces mortality and...

CHAMPION PHOENIX: Cangrelor compared with clopidogrel improves efficiency without increasing bleeding in patients undergoing angioplasty

Background: Oral antiplatelet agents have a limitation in their duration of action and bioavailability. Cangrelor is an intravenous adenosine diphosphate (ADP) inhibitor that has...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....